Erudio Healtherudio.com
Clinical trial · no report yet · Phase not applicable
PROSINT
Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate Cancer
- NCT02570919 ↗
- Completed
- Fundacao Champalimaud
- Focused
We haven't built an HCP commentary report on PROSINT (intermediate-risk prostate cancer; tests no drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PROSINT so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase II Randomized Study Comparing Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy (IGRT) With Urethral Sparing for Intermediate Risk Prostate Cancer
- Phase
- Phase not applicable
- Status
- Completed
- Conditions
- PROSTATE CANCER
- Interventions
- IGRT 45 Gy in 5 fractions of 9 Gy; IGRT 24 Gy single dose
- Arms
- IGRT 45 Gy in 5 fractions of 9 Gy · Active comparator
- IGRT 24 Gy single dose · Experimental
- Enrollment
- 30
- Primary outcomes
- Number of patients with treatment-related adverse events as assessed by Common Toxicity Criteria for Adverse Effects v4.0
- Sponsor
- Fundacao Champalimaud
- Start
- Sep 1, 2015
- Primary completion
- Sep 30, 2017
- Results posted
- No
- Registry record
- NCT02570919 · updated Jul 23, 2019
Publications
linked from the registry- Greco C, Pares O, Pimentel N, Louro V, Santiago I, Vieira S, Stroom J, Mateus D, Soares A, Marques J, Freitas E, Coelho G, Seixas M, Lopez-Beltran A, Fuks Z. Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):700-708. doi: 10.1001/jamaoncol.2021.0039. PubMed 33704378
- Bodo S, Campagne C, Thin TH, Higginson DS, Vargas HA, Hua G, Fuller JD, Ackerstaff E, Russell J, Zhang Z, Klingler S, Cho H, Kaag MG, Mazaheri Y, Rimner A, Manova-Todorova K, Epel B, Zatcky J, Cleary CR, Rao SS, Yamada Y, Zelefsky MJ, Halpern HJ, Koutcher JA, Cordon-Cardo C, Greco C, Haimovitz-Friedman A, Sala E, Powell SN, Kolesnick R, Fuks Z. Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury. J Clin Invest. 2019 Feb 1;129(2):786-801. doi: 10.1172/JCI97631. Epub 2019 Jan 14. PubMed 30480549